A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis

Journal of Cancer Research and Clinical Oncology

Volumn 131, Issue 2, 2005, Pages 129-136

  Wang, Xia ^a   Hou, Min ^a   Tan, Li ^a   Sun, Xinghui ^a   Zhang, Yuqing ^a   Li, Ping ^a   Zhu, Yunsong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Hybrid protein; Tumor cell invasion; Urokinase plasminogen activator

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; FIBRONECTIN; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; INOCULATION; LUNG CARCINOMA; LYMPH NODE METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CARCINOMA, GIANT CELL; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEINS; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 13244256811     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0623-2     Document Type: Article

References (41)

1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:1-22
2. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563-572
3. Sidenius N, Blasi F (2003) The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22:205-222
4. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activator system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:25-40
5. Wang Y (2001) The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev 21:146-170
6. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K (1991) Cellular receptor for urokinase plasminogen activator. Carboxyl- terminal processing and membrane anchoring by glycosyl- phosphatidylinositol. J Biol Chem 266:1926-1933
7. Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Dano K (1991) The ligand-binding domain of the cell surface receptor for urokinase- type plasminogen activator. J Biol Chem 266:7842-7847
8. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32380-32388
9. Schmitt M, Wilhelm OG, Reuning U, Kruger A, Harbeck N, Lengyel E, Magdolen V (2000) The urokinase plasminogen activator system as a novel target for tumor therapy. Fibrinolysis 14:114-132
10. He C, He P, Liu LP, Zhu YS (2001) Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells. J Cancer Res Clin Oncol 127:180-186
11. Liao JH, Xu SH, Tang HB, Lian FZ, Zhu YS (2001) Antisense RNA for urokinase receptor inhibits the invasiveness and metastasis of lung carcinoma. Chin J Pathol 30:357-360
12. Tian Y, Shen JQ, Li P, Zhu YS (2000) The protection function of the PAI-2 from TNF-α is dependent upon its protein binding domain. Acta Biochim Biophys Sincia 32:175-178
13. Dickinson JL, Norris BJ, Jensen PH, Antalis TM (1998) The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-alpha induced apoptosis. Cell Death Differ 5:163-171
14. Ballance DJ, Marshall JM, Cottingham IR, Steven J, Berry SJ, Cederholm-Williams SA, Goodey AR, Courtney M (1992) A hybrid protein of urokinase growth-factor domain and plasminogen- activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor. Eur J Biochem 207:177-183
15. Xu SH, Liao JH, Zhu YS (2000) Inhibition of invasiveness of human breast cancer cells by antisense RNA for urokinase receptor. Chin J Biochem Mol Biol 16:814-819
16. Tian Y, Shen JQ, Li P, Song HY, Zhu YS (2000) Biochemical characterization of PAI-2 and its mutants. Acta Biochim Biophys Sincia 32:126-132
17. Wang X, Li P, Zhang YQ, Hou M, Sun XH, Tan L, Zhu YS (2003) Biological function of fusion protein ATF-PAI2CD. Acta Biochim Biophys Sincia 35:624-628
18. Wang X, Hou M, Sun XH, Li P, Zhang YQ, Tan L, Zhu YS () Construction and expression of human ATF-PAI-2CD fused gene. Chin J Biochem Mol Biol Revised
19. Busk M, Pytela R, Sheppard D (1992) Characterization of the integrin alpha v beta 6 as a fibronectin-binding protein. J Biol Chem 267:5790-5796
20. Hall DE, Neugebauer KM, Reichardt LF (1987) Embryonic neural retinal cell response to extracellular matrix proteins: developmental changes and effects of the cell substratum attachment antibody (CSAT). J Cell Biol 104:623-634
21. Kobayashi H, Moniwa N, Gotoh J, Sugimura M, Terao T (1994) Role of activated protein C in facilitating basement membrane invasion by tumor cells. Cancer Res 54:261-267
22. Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932-943
23. Cox G, Steward WP, O'Byrne KJ (1999) The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax 54:169-179
24. Mazar AP (2001) The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs 12:387-400
25. Shinkfield MNF, Burnand KG, Balance DJ, Zitka M, Eastham D (1992) The effect of recombinant plasminogen activator inhibitor 2(PAI-2) on the growth of a human tumor cell line in vitro and in vivo. Fibrinolysis 6 [Suppl 4]:59-65
26. Praus M, Wauterickx K, Collen D, Gerard RD (1999) Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Ther 6:227-236
27. Evans DM, Lin PL (1995) Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Am Surg 61:692-697
28. Kobayashi H, Gotoh J, Shinohara H, Moniwa N, Terao T (1994) Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemost 71:474-480
29. Rabbani SA, Gladu J (2002) Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 62:2390-2397
30. Guo Y, Mazar AP, Lebrun JJ, Rabbani SA (2002) An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res 62:4678-4684
31. Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP, Rabbani SA (2000) A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 14:1400-1410
32. Ploug M, Ostergaard S, Gardsvoll H, Kovalski K, Holst-Hansen C, Holm A, Ossowski L, Dano K (2001) Peptide-derived antagonists of the urokinase receptor, affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 40:12157-12168
33. Billstrom A, Lecander I, Astedt B (1994) Recombinant PAI-2 inhibition of uPA producing tumors in SCID mice. Fibrinolysis 8 [Suppl 1]:56
34. Akiyama SK, Olden K, Yamada KM (1995) Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 14:173-189
35. Ruoslahti E (1997) Integrins as signaling molecules and targets for tumor therapy. Kidney Int 51:1413-1417
36. Boudreau N, Bissell MJ (1998) Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr Opin Cell Biol 10:640-646
37. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ (2003) Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 60:781-791
38. Akamatsu H, Ichihara-Tanaka K, Ozono K, Kamiike W, Matsuda H, Sekiguchi K (1996) Suppression of transformed phenotypes of human fibrosarcoma cells by overexpression of recombinant fibronectin. Cancer Res 56:4541-4546
39. Urtreger A, Porro F, Puricelli L, Werbajh S, Baralle FE, Joffe EBK, Kornblihtt AR, Muro AF (1998) Expression of RGD minus fibronectin that does not form extracellular matrix fibrils is sufficient to decrease tumor metastasis. Int J Cancer 78:233-241
40. Ma Z, Webb DJ, Jo M, Gonias SL (2001) Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 114:3387-3396
41. Nguyen DH, Hussaini IM, Gonias SL (1998) Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 273:8502-8507